SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is seeing significant downward pressure driven by market apprehension surrounding Donald Trump's extended and often incoherent public address, where his discussion of tariffs and Greenland policy raises concerns about global trade stability. Community sentiment is deeply divided, with many expressing alarm over potential economic repercussions while a subset anticipates a swift "buy the dip" recovery from the current volatility.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amidst significant market volatility, fueled by discussions surrounding former President Trump's public statements on geopolitical issues, including Greenland and proposed tariffs, which are sparking international concern and market reactions. Community chatter is highly polarized, with supporters pointing to a new digital token initiative as a potential short squeeze catalyst, while critics link the former President's rhetoric to broader market instability and question the stock's underlying value.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is highly active amidst intense discussions fueled by geopolitical developments, specifically related to rhetoric from Davos concerning Greenland and potential tariffs impacting European allies. Community sentiment is bifurcated, with many anticipating continued declines from global instability and upcoming interest rate decisions, while a significant portion of traders are actively buying the dip, expecting a customary market rebound despite the contentious headlines.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a focal point of market discussion after recently upgrading its bid for Warner Bros. Discovery assets to an all-cash offer, a strategic move generating debate about its long-term growth prospects ahead of the upcoming earnings report. Community sentiment is sharply divided, with many seeing the stock as oversold and ripe for a rebound, while others express caution regarding the deal's implications and broader market headwinds.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending dramatically after announcing promising Phase 1 clinical trial results for its oral drug, soquelitinib, treating moderate to severe atopic dermatitis with strong efficacy and a favorable safety profile. The market is actively discussing the drug's potential, especially for patients resistant to current therapies, driving speculation of significant upside and a short squeeze, though some caution against the early trial stage and potential dilution.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending following a significant non-exclusive licensing agreement with Pfizer for its Matrix-M adjuvant technology, widely seen by the community as a validation of its core platform. This development has fueled expectations of further partnerships and a potential short squeeze, with many closely watching how management addresses continued activist investor pressure for enhanced shareholder value.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple (AAPL) is currently experiencing highly polarized community sentiment, with many expressing frustration over its recent price decline, perceived lack of AI innovation, and broader market weakness. However, a strong counter-narrative highlights the stock as deeply oversold with historically low RSI levels, presenting a significant "buy the dip" opportunity ahead of its anticipated strong holiday quarter earnings. Geopolitical tensions and ongoing tariff discussions are further fueling volatility and shaping investor outlook on the tech giant.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is experiencing a surge in attention following a pivotal FDA meeting for its ANKTIVA bladder cancer treatment, where regulators reportedly indicated no requirement for new clinical trials and requested additional data for submission within 30 days. This news has ignited strong community discussion, with investors buzzing about a potential short squeeze and highlighting ANKTIVA's broad therapeutic promise across various cancer indications. The stock's robust performance amid a challenging market is drawing significant interest, as many anticipate further positive developments and substantial long-term growth for this biotech company.

ProShares Trust - ProShares Ultra VIX Short-Term Futures ETF 1.5x Shares

ProShares Ultra VIX Short-Term Futures ETF

ProShares Ultra VIX Short-Term Futures ETF ($UVXY) is actively trending as traders weigh potential market volatility driven by discussions surrounding recent geopolitical developments, including international tariffs, and the anticipated Bank of Japan rate hike. The community is sharply divided, with many actively debating short positions on $UVXY due to its inherent decay, while others anticipate a volatility spike, expressing frustration over its subdued movement despite broader market fluctuations.

Top Wealth Group Holding Ltd. operates as a holding company, which provides caviar and caviar-based gourmet products. It focuses on supplying sturgeon caviar to customers under its own brand, Imperial Cristal Caviar. The company was founded by Kim Kwan Kings Wong on February 1, 2023 and is headquartered in Hong Kong.

Top Wealth Group Holding Ltd. - Ordinary Shares - Class A

Top Wealth Group Holding Ltd.

Top Wealth Group Holding is trending following news of its strategic acquisition of a luxury wine authentication and trading business, diversifying its market beyond caviar. This has ignited significant discussion among traders, with many anticipating further price movement and highlighting strong volume, while others express concerns about a recent public offering and potential dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Revance Therapeutics surged more than 16% on Monday morning, reaching over a month’s high, leading to a jump in retail chatter on Stocktwits.The surge followed a proposal from privately held Swiss medical aesthetics company Teoxane to acquire the anti-wrinkle injection maker for $3.60 per share in cash.&nbsp;The offer represents a 16% premium over the $3.10-per-share agreement with Crown Laboratories&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rvnc-stock-tanks-after-crown-labs-halves-takeover-price/cJabclHRig">announced</a> last month.Revance has yet to comment publicly on the proposal, but the news triggered a spike in message volume on Stocktwits, where retail sentiment remained cautious with a ‘neutral’ score.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/RVNC_sentiment_and_message_volume_Jan_6_1855360b7a.png" alt="RVNC sentiment and message volume Jan 6.png" width="1318" height="324"><figcaption>RVNC sentiment and message volume Jan 6 as of 10:45 am ET | source: Stocktwits</figcaption></figure>Last year, Crown agreed to purchase Revance for $6.66 per share, but the deal faced delays due to a dispute with Teoxane over Revance’s breach of a 2020 distribution agreement.&nbsp;The agreement had made Revance the exclusive commercialization partner for Teoxane’s dermal fillers. After resolving the dispute, Revance and Crown amended their deal, slashing the takeover price by more than half, reducing it to approximately $323 million.Teoxane currently holds 6.2% of Revance’s outstanding shares.&nbsp;Despite the uptick in shares following the Teoxane proposal, Revance's stock has struggled recently, plunging around 65% last year.Last year, Revance Therapeutics announced the commercial launch of DAXXIFY for injection for the treatment of cervical dystonia, marking its entry into the expanding U.S. therapeutics neurotoxin market, which could play a role in reshaping its future prospects.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Revance Therapeutics Stock’s Retail Sentiment Muted Even As Teoxane Makes Better Offer Than Crown Labs

The offer represents a 16% premium over the $3.10-per-share agreement with Crown Laboratories announced last month.

Equity

Shares of Revance Therapeutics Inc. plummeted over 20% to a four-month low Monday after private skincare firm Crown Laboratories drastically reduced its takeover offer.Crown will now acquire Revance in an all-cash deal valued at $3.10 per share, down from the initial August agreement of $6.66 per share.&nbsp;The revised deal, worth about $325 million in total equity, marks an 18.9% discount to Revance’s Dec. 6 closing price.&nbsp;The acquisition will make Revance a private company, with the deal expected to close in the first quarter of 2025.The price cut follows a notice received by Revance in September alleging violations of an exclusive distribution agreement with Teoxane.&nbsp;Both companies acknowledged that these violations could significantly impact Revance’s profitability and cash flows, prompting the adjustment.<figure class="image"><img style="aspect-ratio:1314/320;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_09_at_11_31_10_AM_0b2b5cca48.png" alt="Screenshot 2024-12-09 at 11.31.10 AM.png" width="1314" height="320"><figcaption>RVNC sentiment and message volume on Dec. 9 as of 11:30 am ET | source: Stocktwits</figcaption></figure>Retail sentiment on Stocktwits turned sharply bearish, accompanied by ‘extremely high’ message volume as investors expressed frustration.&nbsp;Posts highlighted disappointment with the slashed valuation and uncertainty about Revance’s future.<stembedurl>https://stocktwits.com/Hedgieguy75/message/595701639</stembedurl><stembedurl>https://stocktwits.com/jamstah/message/595671321</stembedurl>Revance, known for its anti-wrinkle injections, has faced a challenging year, with shares down 56.5% so far this year.For updates and corrections email newsroom[at]stocktwits[dot]com.

Revance Therapeutics Stock Plummets To 4-Month Low As Crown Labs Halves Takeover Offer: Retail Fumes

The price cut follows a notice received by Revance in September alleging violations of an exclusive distribution agreement with Teoxane.

Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.

Revance Therapeutics Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

RVNC
Revance Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest RVNC News

RVNCRevance Therapeutics Inc